中医药治疗中晚期非小细胞肺癌文献计量分析

陆颖等

摘要：目的 基于文献分析探讨国内中医药治疗中晚期非小细胞肺癌的临床研究现状。方法 计算机检索PubMed、Cochrane Library、Web of Science、EBSCOhost、ScienceDirect、中国生物医学文献数据库（CBM）、中国知识资源总库（CNKI）、中文科技期刊数据库（VIP）、万方数据库中有关中医药治疗中晚期非小细胞肺癌临床研究文献，检索时间2014年3月6日。筛选符合纳入标准的随机、半随机临床对照试验，从发文时间、文献来源、发文机构、合作情况、试验类型5方面进行计量学分析，探讨本领域的科研状况。结果 共432篇文献符合纳入标准。文献数量总体呈上升趋势，学术期刊是文献主要来源，发文较多的机构主要集中在广东、上海、北京，合著论文比例高，国内同一科研单位/院校合作为主，随机对照试验的研究质量正在提高。结论 中医药治疗中晚期非小细胞肺癌临床研究的数量和质量都有不同程度的提高，本领域具有广阔的研究前景。

关键词：中晚期非小细胞肺癌；中医药疗法；文献计量学

DOI：10.3969/j.issn.1005-5304.2015.09.013

中图分类号：R2-05；R273.42 文献标识码：A 文章编号：1005-5304（2015）09-0044-04

Bibliometric Analysis on Traditional Chinese Medicine Treatment for Mid-advanced Non-small Cell Lung Cancer LU Ying1， LI Jie1， CHEN Chi1， XU Ling2 （1.Shanghai Qigong Institute， Shanghai 200030， China；2.Longhua Hospital Affiliated Shanghai University of TCM， Shanghai 200032， China）

Abstract：Objective To discuss the clinical research status of traditional Chinese medicine treatment for mid-advanced non-small cell lung cancer based on literature analysis. Methods Clinical research articles about TCM treatment for mid-advanced non-small cell lung cancer were retrieved from PubMed， Cochrane Library， Web of Science， EBSCOhost， ScienceDirect， CBM， CNKI， VIP and Wanfang Data in March 6， 2014. RCTs and Q-RCTs were identified by retrieving. Metrology analysis was conducted from the aspects of publication time， article sources， publication organizations， cooperation and trial types， with a purpose to discuss the research status of this domain. Results Totally 432 articles were considered to be eligible for inclusion. The number of articles was on the rise. Academic journals were the most important sources of these articles. Publication organizations in Guangdong， Shanghai and Beijing produced the most articles. Cooperative researches increased， especially the cooperation between the same research units/universities. Research quality of RCT is increasing. Conclusion The quantity and quality of clinical researches on TCM treatment for mid-advanced non-small cell lung cancer have improved in different degrees. This domain shows great research prospect.

Key words：mid-advanced non-small cell lung cancer；traditional Chinese medicine；bibliometrics

據世界卫生组织报道，2012年全球癌症死亡病例约为820万例，预计未来20年将上升到每年1300万例[1]。在我国，根据中国肿瘤登记中心发布的最新数据，肺癌位居我国恶性肿瘤发病率及死亡率首位[2]。非小细胞肺癌（NSCLC）约占肺癌的80%～85%，约有70%NSCLC患者确诊时已为晚期。对于肿瘤患者，综合治疗理念已得到普遍认同[3]。近年来，中医药参与晚期NSCLC的综合治疗中，在稳定瘤灶、延长带瘤生存时间、增加机体免疫功能、改善临床症状、提高生活质量、减轻放化疗毒副作用等方面显示出一定的疗效和优势[4]。……